Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
baclofen, phenibut, GBL +1 morebaclofen, phenibut, GBL, 1,4-butanediol show less
GHB
γ-hydroxybutyric acid
GHB (gamma-hydroxybutyric acid) — G, liquid G, liquid ecstasy — is a CNS depressant of the hydroxy acid class. It is a structural analog of GABA, the brain's primary inhibitory neurotransmitter, differing by a single molecular substitution. GHB suppresses brain activity through GABA-B activation, producing the sedation, relaxation, and euphoria characteristic of depressants.
GHB (gamma-hydroxybutyric acid) is a naturally-occurring depressant of the hydroxy acid class. It is structurally derived from GABA, differing only by a hydroxyl group in place of the amino group. GHB is a low-affinity GABA-B receptor agonist,[1] producing its effects by broadly suppressing CNS arousal through inhibitory signaling.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
baclofen, phenibut, GBL +1 morebaclofen, phenibut, GBL, 1,4-butanediol show less
Henri Laborit first investigated GHB clinically in 1960, designing it as a tool to study inhibitory brain signaling directly.[1] It entered American health food stores in the 1980s as a bodybuilding and sleep supplement, then gained notoriety as a date-rape drug and was placed on US Schedule I in 2000. Pharmaceutical sodium oxybate (Xyrem) holds FDA approval for narcolepsy under a unique Schedule III exception.[2]
Subjective effects include euphoria, disinhibition, muscle relaxation, anxiolysis, and amnesia. The experience resembles compressed alcohol intoxication — a warm, sociable loosening that tips quickly into heavy sedation as the dose rises. Nausea, dizziness, memory blackouts, and sudden loss of consciousness are characteristic unwanted effects.
GHB produces rapid physical dependence, and only a roughly five-fold span in blood concentration separates euphoria from lethal respiratory depression.[3] Small dose increases cause disproportionately large jumps in blood levels because the body's processing capacity saturates;[4] no antidote exists,[5] and withdrawal progresses faster and more dangerously than with alcohol or benzodiazepines.[6][7] Six decades of clinical research underpin the current understanding, though the identity and function of high-affinity GHB binding sites in the brain remain actively debated.[8][9]
History[edit]
Discovery
GHB was first synthesized in 1874, but systematic investigation began when French biochemist Henri Laborit explored it in 1960 as a blood-brain barrier-permeable structural analog of GABA.[1] His goal was to study inhibitory brain signaling directly — GABA itself cannot cross the barrier. Early clinical work tested GHB as an anesthetic and a potential treatment for narcolepsy and alcohol dependence.[10]
Clinical and cultural significance
In the 1980s, GHB appeared in American health food stores as a bodybuilding and sleep supplement, driven by evidence that bedtime doses doubled growth hormone secretion.[11] Recreational use expanded through the 1990s,[10] and GHB gained infamy for its role in drug-facilitated sexual assault — its colorless, near-odorless liquid form and amnesia-producing properties made covert administration hard to detect. In the United Kingdom, GHB was designated a Class C controlled substance in 2003.[12]
Prohibition and modern use
The Hillory J. Farias and Samantha Reid Date-Rape Drug prohibition Act of 2000 placed illicit GHB on US Schedule I,[13] while sodium oxybate (Xyrem) received FDA approval for narcolepsy in 2002.[1][2][14] In Italy and Austria, sodium oxybate (Alcover) has been approved since the 1990s for alcohol withdrawal and dependence maintenance.[15][16] Low-sodium oxybate (Xywav) was approved for narcolepsy in 2020 and idiopathic hypersomnia in 2021.[17]
The name liquid ecstasy became common in nightlife settings during the 1990s, though GHB is pharmacologically unrelated to MDMA — the label reflects the euphoric sociability of low doses rather than any shared mechanism. G and liquid G are the most prevalent shorthand in club and chemsex communities. The prodrug GBL is often treated as interchangeable with GHB despite different potency and onset characteristics, a conflation that contributes to dosing errors.
Chemistry[edit]
Structure
GHB (4-hydroxybutanoic acid) is a short-chain hydroxy acid and a close structural relative of GABA, the brain's primary inhibitory neurotransmitter. The two molecules differ by a single substitution: GHB replaces GABA's amino group with a hydroxyl group.
That change gives GHB the ability to cross the blood-brain barrier — something GABA itself cannot do. GHB does not bind significantly to plasma proteins,[4] so it moves freely in the bloodstream.
| Molecular formula | C₄H₈O₃ |
| Molecular weight | 104.10 g/mol |
Prodrugs and precursors
Two widely available industrial chemicals function as GHB prodrugs: GBL (gamma-butyrolactone) and 1,4-BD (1,4-butanediol). GBL converts to GHB within about a minute; 1,4-BD follows a slightly longer conversion pathway.[18] Neither is controlled under the UN Convention on Psychotropic Substances, creating a legal gap through which pharmacologically equivalent GHB exposure remains accessible.[18]
Pharmacology[edit]
Mechanism of action
GHB works primarily by activating GABA-B receptors — the same inhibitory receptors that baclofen targets, though at weaker potency.[5] Blocking these receptors in animal studies eliminates GHB's sedation, hypothermia, and motor effects entirely,[19] confirming GABA-B as the primary mechanism.
Effects escalate with dose[5][18][3]: low concentrations produce mild neuromodulation; recreational concentrations produce sedation and muscle relaxation; overdose concentrations cause coma. A separate set of high-affinity GHB binding sites has been identified,[8] but their function in living brain tissue remains unresolved.[9][20]
Pharmacokinetics
GHB is taken orally; effects begin within 5–45 minutes and blood levels peak at 20–40 minutes.[3][18] The body breaks it down through liver pathways into ordinary cellular metabolites,[21] giving it a short half-life of 20–60 minutes[18] and a narrow detection window — about 6 hours in blood and 10 hours in urine.[18] Absorption and elimination both saturate at higher doses, so small increases can cause disproportionately large jumps in blood levels.[4]
Neuroscience[edit]
Where it acts
Endogenous GHB concentrates in the hippocampus, cortex, and the brain's dopamine-producing regions.[22] At low concentrations it suppresses dopamine release; at higher concentrations, GABA-B activation initially suppresses dopamine neurons, but a rebound effect surge in dopamine follows as the drug clears — a mechanism thought to underlie the brief euphoric window before sedation takes hold.
GHB taken at bedtime robustly deepens slow-wave sleep and doubles growth hormone secretion.[11] It does this by suppressing brainstem arousal centers through GABA-B activation.[23]
Why it matters
The dopamine rebound model helps explain compulsive redosing: as the euphoric window closes, the drive to reopen it encourages another dose. GHB's ability to deepen slow-wave sleep without substantially disrupting REM has made it both a therapeutic agent and a research tool. An active Phase 2 trial (NCT06421532) is testing whether GHB-enhanced sleep can improve brain waste clearance.
The physiological function of endogenous GHB signaling remains unclear after three decades of research. Whether α4β1δ GABA-A receptors are the native high-affinity GHB target remains contested.[8][9] A systematic review found cognitive impairment in chronic heavy users,[24] but whether this reflects direct brain damage or polysubstance confounding is unresolved.
Subjective Effects[edit]
GHB's experience is defined by extreme dose sensitivity. The entire range from mild relaxation to loss of consciousness compresses into a narrow dosing window, and liquid concentration variability means a measured volume from one batch can behave very differently from the same volume of another. Social environments foreground euphoria and disinhibition; quiet settings accelerate the slide toward sedation and sleep.
Compared to alcohol, GHB produces a qualitatively similar depressant arc — but faster, shorter, and far steeper. The escalation from comfortable intoxication to incapacitation is more abrupt than alcohol drinkers expect. Relative to baclofen, the other GABA-B receptor agonist encountered recreationally, GHB carries stronger euphoric effects and a significantly more dangerous dose-response profile.
Henri Laborit first investigated GHB clinically in 1960, designing it as a blood-brain barrier-permeable structural analog of GABA.[2] It entered American health food stores in the 1980s as a bodybuilding supplement, gained notoriety as a date-rape drug, and was placed on US Schedule I in 2000. Pharmaceutical sodium oxybate (Xyrem) holds FDA approval for narcolepsy under a unique Schedule III exception.[3]
Subjective effects include euphoria, disinhibition, anxiolysis, muscle relaxation, and amnesia. The experience compresses the arc of alcohol intoxication into a shorter, steeper curve — a warm prosocial loosening that tips rapidly into heavy sedation as dose increases. Nausea, dizziness, memory blackouts, and sudden loss of consciousness are characteristic unsought effects.
GHB produces rapid physical dependence, and roughly a five-fold plasma concentration span separates euphoria from lethal respiratory depression.[4] Capacity-limited metabolism means small dose increases produce disproportionate jumps in blood levels;[5] no antidote exists,[6] and withdrawal progresses faster than alcohol or benzodiazepine withdrawal.[7][8] Six decades of clinical data support the current understanding, though the identity and function of endogenous high-affinity GHB binding sites remain contested.[9][10]
History[edit]
Discovery
GHB was first synthesized in 1874, but systematic investigation began only when French biochemist Henri Laborit explored it in 1960 as a blood-brain barrier-permeable structural analog of GABA.[2] Laborit's goal was to study inhibitory neurotransmission directly in the brain — GABA itself cannot cross the barrier. Early clinical work tested GHB as an intravenous anesthetic, a model for absence seizures, and a potential treatment for narcolepsy and alcohol dependence.[11]
Clinical and cultural significance
During the 1980s, GHB entered American health food stores as a bodybuilding and sleep supplement, driven by evidence that bedtime doses doubled growth hormone secretion via slow-wave sleep promotion.[12] Recreational use for euphoric and sedative effects expanded through the 1990s,[11] and GHB gained infamy as a drug-facilitated sexual assault agent — its colorless, near-odorless liquid form and amnesia-producing properties made covert administration difficult to detect. In the United Kingdom, GHB was designated a Class C controlled substance in 2003.[13]
Prohibition and modern use
The Hillory J. Farias and Samantha Reid Date-Rape Drug prohibition Act of 2000 placed illicit GHB on US Schedule I,[14] while sodium oxybate (Xyrem) received FDA approval in 2002 for narcolepsy under a unique Schedule III exception with mandatory risk management.[2][3][15] In Italy and Austria, sodium oxybate (Alcover) has been approved since the 1990s for alcohol withdrawal and dependence maintenance.[16][17] Low-sodium oxybate (Xywav) was approved for narcolepsy in 2020 and idiopathic hypersomnia in 2021.[18]
The name liquid ecstasy became common in nightlife settings during the 1990s, though GHB is pharmacologically unrelated to MDMA — the label reflects the euphoric sociability of low doses rather than any shared mechanism. G and liquid G are the most prevalent shorthand in club and chemsex communities. The prodrug GBL is colloquially treated as interchangeable with GHB despite different potency and onset characteristics, a conflation that contributes to dosing errors.
Chemistry[edit]
Structure
4-Hydroxybutanoic acid (GHB) is a short-chain hydroxy acid and structural analog of the inhibitory neurotransmitter GABA. The molecule consists of a four-carbon aliphatic chain bearing a terminal hydroxyl group and a carboxylic acid, differing from GABA only in the substitution of the amino group at C-4 with a hydroxyl group. This substitution confers blood-brain barrier permeability that GABA itself lacks — the property that motivated Laborit's original interest in the compound.
| Molecular formula | C₄H₈O₃ |
| Molecular weight | 104.10 g/mol |
Stereochemistry
GHB is achiral — the molecule contains no stereocenters. The endogenous and exogenous forms are chemically identical.
Physical properties
The free acid is a hygroscopic solid at room temperature. The sodium salt (sodium oxybate) is a white crystalline powder, highly water-soluble due to its dual polar functional groups. GHB does not undergo significant plasma protein binding.[5] In both clinical and illicit contexts, GHB is typically encountered as an aqueous solution or as the sodium salt.
Prodrugs and precursors
Two widely available industrial chemicals serve as GHB prodrugs: γ-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). GBL is rapidly hydrolyzed to GHB by peripheral lactonases (half-life approximately one minute), while 1,4-BD is converted via alcohol dehydrogenase and aldehyde dehydrogenase pathways.[19] Neither precursor is scheduled under the UN Convention on Psychotropic Substances, creating a persistent legal gap through which pharmacologically equivalent GHB exposure remains accessible.[19]
Pharmacology[edit]
Mechanism of action
GHB produces its pharmacological effects primarily through GABA-B receptor agonism, though at substantially weaker potency than the prototypical GABA-B receptor agonist baclofen.[6] GABA-B antagonists fully prevent GHB-induced sedation, hypothermia, and motor impairment in animal models,[1] confirming this receptor as the primary mediator of its clinical and recreational effects.
A separate population of high-affinity GHB binding sites has been identified, including at α4β1δ GABA-A receptors.[9] Attempts to replicate these effects in native brain tissue have not succeeded,[10] and the functional significance of these sites remains unresolved.[20]
The prevailing model holds that effects are dose-dependent[6][19][4]: at low concentrations, high-affinity sites modulate dopamine tone and produce mild neuromodulation; at recreational and therapeutic concentrations, GABA-B activation predominates, producing sedation, muscle relaxation, and respiratory depression; at overdose concentrations, profound GABA-B agonism causes coma and potentially death.
Pharmacokinetics
GHB is taken almost exclusively by the oral route, with absorption onset within 5–45 minutes and peak plasma concentrations at 20–40 minutes.[4][19] Plasma half-life is short, ranging from 20 to 60 minutes,[19] and urinary excretion accounts for only 1–5% of the dose.[4]
The defining pharmacokinetic feature is nonlinear, capacity-limited kinetics — both absorption and elimination are saturable, meaning small dose increases can produce disproportionately large plasma concentration jumps.[5] GHB enters the brain via monocarboxylate transporter 1 (MCT1), another saturable system that compounds the nonlinear dose-response.[21]
Metabolism proceeds through non-CYP hepatic pathways: oxidation to succinic semialdehyde, then to succinate and entry into the citric acid cycle.[22] Valproate, salicylate, and phenylacetate inhibit this pathway, potentially elevating brain GHB levels — a clinically relevant drug interaction.[22] Detection windows are short: approximately 6 hours in blood and 10 hours in urine.[19]
Neuroscience[edit]
Where it acts
Endogenous GHB is concentrated in the hippocampus, cortex, and dopaminergic structures including the striatum, frontal cortex, and ventral tegmental area.[23] The dopaminergic system is a primary downstream target: at low concentrations, GHB suppresses dopamine release through high-affinity receptor stimulation; at higher exogenous concentrations, GABA-B activation initially suppresses dopamine neurons, but upon clearance, a rebound effect increase in dopamine release occurs — a mechanism proposed to underlie the brief euphoric phase that precedes sedation.
GHB administered at bedtime robustly promotes slow-wave sleep and doubles growth hormone secretion.[12] GABA-B-mediated inhibition of brainstem arousal nuclei — particularly the laterodorsal tegmentum and raphe nuclei — directly suppresses the ascending arousal system, producing sedation and hypnosis.[24]
Why it matters
GHB's biphasic dopamine effects — initial suppression followed by rebound release — map onto reward circuitry models: the euphoric window may reflect the transition from tonic dopamine inhibition to phasic release as high-affinity receptors desensitize, driving the compulsive redosing observed in dependent users. Its capacity to consolidate and deepen slow-wave sleep without substantially disrupting REM architecture positions GHB as both a therapeutic agent and a pharmacological tool for probing sleep homeostasis. An active Phase 2 trial (NCT06421532) is testing whether GHB-enhanced slow-wave sleep can improve brain waste clearance through the glymphatic system.
The physiological function of endogenous GHB signaling remains unclear after three decades of research — its regional distribution overlaps with dopaminergic systems, but no specific homeostatic role has been definitively assigned. Whether α4β1δ GABA-A receptors are the native high-affinity GHB target remains contested.[9][10] A systematic review found cognitive impairment in chronic heavy users,[25] but whether this reflects direct neurotoxicity or confounding polysubstance use is unresolved.
Subjective Effects[edit]
The GHB experience is defined by extreme sensitivity to dose precision. Unlike most depressants, where dose-response scales roughly linearly, GHB's capacity-limited metabolism compresses the entire experiential range — from subtle relaxation to loss of consciousness — into a narrow dosing window. Social environments tend to foreground the disinhibiting, empathogenic qualities, while quiet or solitary settings accelerate the transition to sedation and sleep. Liquid concentration variability represents a major source of unintentional overdose, as batches differ unpredictably in strength.
Compared to alcohol, GHB produces a qualitatively similar but more compressed depressant arc — faster onset, shorter duration, and a markedly steeper escalation from intoxication to incapacitation. Relative to baclofen, the other GABA-B receptor agonist encountered recreationally, GHB is distinguished by stronger euphoric and prosocial effects and a far more dangerous dose-response profile.
Effect Grid
At common doses (1.5–2.5 g oral), the full GHB experience manifests: pronounced euphoria, strong disinhibition, and marked anxiolysis. Sociability and empathy enhancement are prominent, as is sexual arousal enhancement — effects that account for GHB's prevalence in social and chemsex contexts. Memory suppression becomes noticeable; events during the peak may be poorly recalled afterward.
Physically, substantial muscle relaxation and moderate sedation dominate. Motor incoordination becomes apparent — gait may be unsteady and fine motor control is impaired. Nausea occurs in some individuals. Drowsiness can progress to sleep, particularly in quiet settings.
The experience lasts 1.5–2.5 hours. The steep dose-response curve means that even small additional amounts within this range produce disproportionate increases in sedation and impairment.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Dreaming enhancement · Music enhancement · Touch enhancement · Visual acuity suppression · Visual haze / noise · Depth perception distortion · Auditory enhancement · Visual processing suppression · External hallucinations
Visual haze / noise · Depth perception distortion · Auditory enhancement · Visual processing suppression · External hallucinations
Bodily heaviness · Dizziness · Physical fatigue · Tactile euphoria · Laughter fits · Nausea · Sexual arousal enhancement · Spontaneous body sensations · Vomiting · Breathing alteration · Nystagmus (eye wobbles) · Body schema distortion · Headache · Pain suppression · Stimulation · Abnormal heartbeat · Heart rate perception changes · Involuntary body movements · Temperature dysregulation · Tingling / electric sensations · Trembling · Pupil constriction · Salivation · Vibrations / buzzing · Bodily dissociation
Tactile euphoria · Laughter fits · Nausea · Sexual arousal enhancement · Spontaneous body sensations · Vomiting · Breathing alteration · Nystagmus (eye wobbles) · Body schema distortion · Headache · Pain suppression · Stimulation · Heart rate perception changes · Involuntary body movements · Temperature dysregulation · Tingling / electric sensations · Trembling · Pupil constriction · Salivation · Vibrations / buzzing · Bodily dissociation
Memory suppression · Analysis suppression · Cognitive euphoria · Cognitive fatigue · Confusion · Delusions of sobriety · Language suppression · Memory fragmentation · Suggestibility enhancement · Thought deceleration · Motivation suppression · Openness enhancement · Thought disorganization · Humor enhancement · Aesthetic enhancement · Immersion enhancement · Cognitive dysphoria · Language enhancement · Introspection enhancement · Motivation enhancement · Amnesia · Delirium
Cognitive fatigue · Confusion · Language suppression · Memory fragmentation · Suggestibility enhancement · Thought deceleration · Motivation suppression · Openness enhancement · Thought disorganization · Humor enhancement · Aesthetic enhancement · Immersion enhancement · Cognitive dysphoria · Language enhancement · Introspection enhancement · Motivation enhancement · Amnesia · Delirium
Emotional enhancement · Anxiety · Dysphoria · Emotional lability · Irritability
Irritability
Craving · Trust enhancement · Emotional susceptibility · Communication enhancement · Automaticity · Sociability suppression · Depersonalization · Derealization · Cognitive disconnection
Automaticity · Sociability suppression · Depersonalization · Derealization · Cognitive disconnection
Timeline
First awareness of effects: subtle warmth, faint mood shift, and a sense that something has changed. The wide onset range (5–30 min) reflects variable gastric absorption and GHB's capacity-limited uptake.
Effects build rapidly. Euphoria, anxiolysis, and muscle relaxation intensify over 10–20 minutes. Disinhibition becomes noticeable.
Maximum intensity: pronounced euphoria, strong disinhibition, marked sedation, and muscle relaxation. Amnesia may be present. At common doses, this is a warm, sociable, physically relaxed state.
Effects decline relatively quickly (15–30 min) owing to GHB's short plasma half-life of 20–60 minutes. Sedation and muscle relaxation fade first; mild residual euphoria may linger briefly.
Residual drowsiness, mild relaxation, and a sense of restfulness may persist for 2–4 hours. Some users report improved sleep quality if taken at bedtime. Cognitive and motor performance may remain subtly impaired beyond subjective recovery.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- Moderate
- Withdrawal
- Severefatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- baclofen · phenibut · GBL
Toxicity
Acute toxicity
GHB has one of the narrowest safety margins of any recreational drug. Blood concentrations producing euphoria are roughly five times lower than those associated with fatal respiratory failure.[3] No antidote exists — treatment means keeping the airway open until the drug clears.[5][3]
That narrow margin exists because both absorption and elimination saturate — small dose increases push blood levels far higher than expected.[4][5] Because GHB clears quickly (half-life 20–60 minutes), most patients recover if the airway is protected. Aspiration from vomiting while unconscious is a significant secondary risk.
Postmortem blood concentrations in GHB deaths averaged 637 mg/L but ranged from 30 to 9,200 mg/L,[25] reflecting extreme individual variability driven by tolerance, co-ingested substances, and metabolic differences.
GHB overdose progresses through sedation, respiratory depression, unconsciousness, and coma. No antidote exists. Place the person in the recovery position to prevent aspiration. Monitor airway, breathing, and circulation. GHB is eliminated rapidly (half-life 20–60 minutes) — spontaneous recovery is possible if the airway is protected. Call emergency services immediately for any person who is unconscious or whose breathing is slowed or irregular.
Organ toxicity
No published evidence links GHB to direct liver, kidney, or heart damage at recreational or therapeutic doses. In pharmacovigilance data from over 260,000 patients treated with sodium oxybate for alcohol dependence, serious adverse events were rare.[15]
Cognitive effects of chronic use
A systematic review found evidence of cognitive impairment at high doses and in chronic heavy users, though the evidence was limited and confounded by polysubstance use.[24]
Psychological risks
The primary acute psychological risk is amnesia — memory suppression occurs at recreational doses[26] and underlies GHB's use in drug-facilitated sexual assault.[27][28] Disinhibition and impaired judgment at low doses increase risk-taking, particularly in sexual contexts.
GHB is a primary chemsex drug among men who have sex with men, with prevalence reaching 20% in some communities.[12] Psychological dependence develops with regular use. Relapse rates exceed 60% within three months of detoxification.[29]
Tolerance and dependence
Tolerance develops within days of continuous use through GABA-B adaptation. The precise timeline has not been established in controlled studies.citation needed
Physical dependence develops with regular use and is a significant clinical concern.[10][7][6] GHB use disorder is described as a growing health problem in several western countries, particularly the Netherlands.[30]
Withdrawal arrives faster than alcohol or benzodiazepine withdrawal[6][7] and can progress rapidly from mild to severe. Initial symptoms — insomnia, anxiety, and tremor — typically resolve in 3–12 days.[10] Severe cases escalate to delirium, psychosis, and seizures.
No FDA- or EMA-approved withdrawal protocol exists. Current approaches include:
- Benzodiazepines: first-line for symptom management, though inadequate for all cases[31]
- Baclofen: a GABA-B agonist used as adjunct for withdrawal and relapse prevention[32][30][12]
- Pharmaceutical GHB tapering (DeTiTap): gradual dose reduction using pharmaceutical-grade GHB, demonstrated as feasible in 23 patients in a specialist setting[31]
Drug Interactions
Alcohol combined with GHB produces additive or synergistic respiratory depression.[3][18] Both suppress brain activity; together they push that suppression toward respiratory failure.
Opioids (including fentanyl, heroin, and methadone) add to respiratory depression through a separate mechanism — opioid receptors rather than GABA-B.[26] This combination is associated with coma and death.
Baclofen combined with GHB produces synergistic GABA-B activation. Under medical supervision, baclofen is used to treat GHB dependence;[12] unsupervised combination carries lethal risk.
GBL and 1,4-BD are GHB prodrugs — combining any of them with GHB effectively constitutes overdose.[18]
Stimulants (amphetamines, cocaine, MDMA) are frequently combined with GHB in chemsex contexts.[33] Stimulants mask GHB's sedative effects and encourage redosing; when the stimulant wears off, accumulated GHB can cause sudden overdose.
Dissociatives (ketamine, PCP) combined with GHB are flagged as lethal-severity interactions in harm reduction databases.safety citation needed Both suppress brain activity through different mechanisms; the combination is considered high-risk.
Valproate, salicylate, and phenylacetate block GHB metabolism, raising brain GHB levels.[21]
HIV protease inhibitors (cobicistat, ritonavir) can dramatically elevate GHB plasma concentrationscitation needed — a recognized safety concern for people using GHB/GBL in chemsex contexts.
Contraindications
7 knownConcurrent CNS depressant use (alcohol, opioids, benzodiazepines, barbiturates, ketamine) is an absolute contraindication — additive respiratory depression can be lethal.[3][18][26]
Concurrent GBL or 1,4-BD use effectively constitutes double-dosing and is an absolute contraindication.[18]
SSADH deficiency: This rare metabolic disorder causes endogenous GHB to accumulate to dangerous levels; exogenous administration is absolutely contraindicated.
Pregnancy: No safety data exist. A single case report describes withdrawal management in a pregnant patient.[34] Use in pregnancy is contraindicated.
Respiratory compromise: Any condition impairing breathing (COPD, sleep apnea, respiratory muscle weakness) increases the risk of GHB-induced respiratory depression.
Valproate and other GHB metabolism inhibitors: Impaired metabolism enhances effects and represents a relative contraindication.[21]
Harm Reduction[edit]
Forms & Identification
GHB is most commonly encountered as a clear, slightly salty liquid of unknown concentration. Two milliliters of one batch may be a light dose while two milliliters of another produces unconsciousness. This concentration variability is the single greatest practical danger.
The prodrugs GBL and 1,4-BD are pharmacologically equivalent to GHB but differ in potency and onset. Treating them as interchangeable with GHB is a common source of serious dosing errors.
Guidelines
- Know the concentration. GHB liquid varies enormously in strength. Never assume one batch matches another. Start with a small test dose from any new source.
- Measure with precision. Use a graduated syringe or measuring device — never estimate by sip or capful.
- Time doses carefully. If redosing, wait at least two hours. Overlapping doses can push rapidly from comfortable to unconscious.
- Eat lightly beforehand. A light meal may slow absorption and reduce nausea, but a full stomach does not prevent overdose.
- Use with a trusted companion. A sober person should know what was taken, how much, and when.
- Choose the setting carefully. Avoid situations where sudden unconsciousness would be dangerous.
Set & Setting
GHB's effects are strongly shaped by environment. Stimulating social settings foreground euphoria and disinhibition; quiet settings accelerate the transition to sedation and sleep.
The narrow gap between desired effects and unconsciousness makes situation especially important. Using near water, at height, while driving, or alone dramatically raises the consequences of sudden incapacitation. A sober companion who knows what was taken and when is a meaningful safety measure.
Aftercare & integration. GHB's short duration means the acute experience resolves quickly, but aftereffects can include lingering grogginess, mild confusion, and fragmented memory. Prioritize sleep, hydration, and a light meal afterward.
Memory gaps can be pieced together with trusted companions when ready. Repeated amnesia episodes indicate the dose is too high. Dosing on a schedule — particularly around the clock — is an early sign of physical dependence. Seeking support before withdrawal becomes medically dangerous is strongly advisable.
Recovery & Support
GHB dependence develops faster than most users expect, particularly with round-the-clock dosing. Withdrawal can be medically dangerous — do not attempt unsupervised withdrawal after sustained daily use. Medical detoxification is strongly recommended, as withdrawal can progress rapidly to delirium and seizures.
Treatment options include benzodiazepine-managed detoxification, baclofen-assisted tapering, and pharmaceutical GHB dose reduction (DeTiTap) in specialist settings. Relapse rates are high; ongoing support through addiction services, peer support groups, or specialized chemsex support programs may improve outcomes.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: The line between heavy sedation and life-threatening overdose is narrow. Red flags: unresponsive to voice or firm touch, slow or irregular breathing, blue-tinged lips or fingertips, vomiting while unconscious, or seizure-like movements.
Immediate steps:
- Call emergency services.
- Place the person in the recovery position (on their side) to prevent choking on vomit.
- Monitor breathing continuously. If breathing stops, begin rescue breathing.
- Do NOT leave the person alone. Do NOT induce vomiting. Do NOT give stimulants to try to wake them.
What to tell the dispatcher: Name the substance (GHB, G, or liquid G), estimated amount and time taken, current symptoms, and whether anything else was consumed. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for GHB. Recovery depends entirely on maintaining the airway until the drug is eliminated — typically within one to two hours.
Legal Status[edit]
GHB occupies an unusual dual legal position — simultaneously a Schedule I controlled substance under illicit law and a Schedule III prescription medication as sodium oxybate in the United States, a bifurcation unique in US drug policy. Internationally, GHB is controlled under Schedule IV of the UN Convention on Psychotropic Substances. The prodrugs GBL and 1,4-BD remain unscheduled in most jurisdictions, creating a persistent gap through which pharmacologically equivalent exposure remains accessible.[18]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (illicit) / Schedule III (Xyrem, Xywav) | Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000 (PL 106-172);[13] FDA-approved formulations under Schedule III with REMS[1] |
| United Kingdom | Class C (Misuse of Drugs Act 1971) | Designated June 2003[12] |
| International (UN) | Schedule IV, Convention on Psychotropic Substances | Added 2001citation needed |
| Italy | Prescription approved (Alcover) | Approved for alcohol withdrawal and dependence maintenance since 1990s[15] |
| Austria | Prescription approved (Alcover) | Approved for alcohol withdrawal and dependence maintenance since 1990s[16] |
| Canada | Schedule III (CDSA) | Controlled since 2000citation needed |
| Australia | Schedule 8 / Prohibited | Prohibited except pharmaceutical usecitation needed |
Legal status varies by jurisdiction and changes over time. This is not legal advice.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- Moderate
- Withdrawal
- Severefatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- baclofen · phenibut · GBL
Toxicity
Acute toxicity
GHB has one of the narrowest margins between desired effects and death among recreational drugs. Plasma concentrations of approximately 100 mg/L produce euphoria; concentrations approaching 500 mg/L are associated with fatal respiratory depression.[4] This roughly five-fold gap arises from capacity-limited metabolism — both absorption and elimination saturate, so small dose increases produce disproportionately large blood-level jumps.[5][6]
Respiratory depression is the primary cause of death.[6][19] No antidote exists — treatment is entirely supportive, focused on maintaining the airway.[6][4] Because GHB's half-life is short (20–60 minutes), patients typically recover if the airway is protected. Aspiration from vomiting while unconscious is a significant secondary risk.
Postmortem blood concentrations in GHB deaths averaged 637 mg/L but ranged from 30 to 9,200 mg/L,[26] reflecting extreme individual variability driven by tolerance, co-ingested substances, and metabolic differences.
GHB overdose progresses through sedation, respiratory depression, unconsciousness, and coma. No antidote exists. Place the person in the recovery position to prevent aspiration. Monitor airway, breathing, and circulation. GHB is eliminated rapidly (half-life 20–60 minutes) — spontaneous recovery is possible if the airway is protected. Call emergency services immediately for any person who is unconscious or whose breathing is slowed or irregular.
Organ toxicity
No published evidence links GHB to direct liver, kidney, or heart damage at recreational or therapeutic doses in the absence of overdose. In pharmacovigilance data from over 260,000 alcohol-dependent patients treated with sodium oxybate, serious adverse events were rare, limited mainly to mild dizziness and vertigo.[16]
Cognitive effects of chronic use
A systematic review found evidence of cognitive impairment at high doses and in chronic heavy recreational users, though the evidence was limited and confounded by polysubstance use.[25]
Psychological risks
The primary acute psychological risk is amnesia — memory suppression occurs at recreational doses and defines much of the GHB experience.[27] This property underlies GHB's use in drug-facilitated sexual assault.[28][29]
At low doses, disinhibition and impaired judgment increase risk-taking behavior, particularly in sexual contexts. GHB is a primary chemsex drug among men who have sex with men, with prevalence reaching 20% in some communities.[13] Chemsex use is associated with increased HIV and STI transmission risk.
Psychological dependence develops with chronic use, driven by euphoria and anxiolysis. Relapse rates exceed 60% within three months of detoxification.[30]
Tolerance and dependence
Tolerance develops within days of continuous use through GABA-B adaptation. The precise timeline has not been established in controlled studies.citation needed
Physical dependence develops with regular use and is a significant clinical concern.[11][8][7] GHB use disorder is described as a growing health problem in several western countries, particularly the Netherlands.[31]
Withdrawal onset is more rapid than alcohol or benzodiazepine withdrawal, with potentially rapid progression from mild to severe symptoms.[7][8] Initial symptoms include insomnia, anxiety, and tremor, typically resolving in 3–12 days.[11] Severe withdrawal can progress to delirium, agitation, psychosis, and seizures.
No FDA- or EMA-approved protocol for GHB withdrawal exists. Current approaches include:
- Benzodiazepines: first-line for symptom management, though inadequate for all cases[32]
- Baclofen: a GABA-B agonist used as adjunct for withdrawal and relapse prevention[33][31][13]
- Pharmaceutical GHB tapering (DeTiTap): gradual dose reduction using pharmaceutical-grade GHB, demonstrated as feasible in 23 patients in a specialist setting[32]
Drug Interactions
Alcohol combined with GHB produces additive or synergistic respiratory depression — alcohol enhances GABAergic tone broadly while GHB activates GABA-B receptors specifically.[4][19]
Opioids (including fentanyl, heroin, methadone, and others) produce additive respiratory depression through separate mechanisms (μ-opioid vs. GABA-B).[27] This combination is associated with coma and death.
Baclofen combined with GHB produces synergistic GABA-B activation. While baclofen is used therapeutically for GHB dependence under medical supervision,[13] unsupervised combination carries lethal risk.
GBL and 1,4-BD are GHB prodrugs — combining any of these with GHB effectively constitutes overdose.[19]
Stimulants (amphetamines, cocaine, MDMA) are frequently combined with GHB in chemsex contexts.[34] The combination is not directly lethal at recreational doses, but stimulants mask GHB's sedative effects, encouraging redosing that dramatically increases overdose risk when the stimulant wears off.
Dissociatives (ketamine, PCP) combined with GHB are flagged as lethal-severity interactions in harm reduction databases. The basis — additive CNS depression from NMDA antagonism plus GABA-B agonism — is plausible, though specific case reports for these combinations were not identified.safety citation needed
Valproate, salicylate, and phenylacetate inhibit GHB metabolism, potentially elevating brain GHB levels.[22]
HIV protease inhibitors (cobicistat, ritonavir) can dramatically elevate GHB plasma concentrations — a recognized safety concern in HIV patients using chemsex GHB/GBL.citation needed
Contraindications
7 knownConcurrent CNS depressant use (alcohol, opioids, benzodiazepines, barbiturates, ketamine) is an absolute contraindication due to lethal additive respiratory depression.[4][19][27]
Concurrent GBL or 1,4-BD use effectively constitutes double-dosing and is an absolute contraindication.[19]
Succinic semialdehyde dehydrogenase (SSADH) deficiency: In this rare metabolic disorder, endogenous GHB already accumulates to dangerous levels; exogenous administration is absolutely contraindicated.
Pregnancy: No safety data exist. A single case report describes withdrawal management in a pregnant patient.[35] Use in pregnancy is contraindicated.
Respiratory compromise: Any condition impairing breathing (COPD, sleep apnea, respiratory muscle weakness) increases the risk of GHB-induced respiratory depression.
Patients on valproate or other GHB metabolism inhibitors: Enhanced effects due to impaired metabolism represent a relative contraindication.[22]
Harm Reduction[edit]
Forms & Identification
GHB is most commonly encountered as a clear, slightly salty liquid of unknown concentration — this variability is the single greatest practical danger. Two milliliters of one batch may be a light dose while two milliliters of another produces loss of consciousness. Volumetric dosing without knowing the concentration of the specific solution is inherently unreliable. The prodrugs GBL and 1,4-BD are pharmacologically equivalent but differ in potency and onset; treating them as interchangeable with GHB is a common and dangerous error.
Guidelines
- Know the concentration. GHB liquid varies enormously in strength. Never assume one batch matches another. Start with a small test dose from any new source.
- Measure with precision. Use a graduated syringe or measuring device — never estimate by sip or capful.
- Time your doses. If redosing, wait at least two hours. The steep dose-response curve means overlapping doses can push rapidly from comfortable to unconscious.
- Eat lightly beforehand. A light meal may slow absorption and reduce nausea, but a full stomach does not prevent overdose.
- Use with a trusted companion. A sober person should know what was taken, how much, and when.
- Choose your setting carefully. Avoid situations where sudden unconsciousness would be dangerous.
Set & Setting
GHB's effects are strongly context-dependent. Stimulating social environments tend to foreground the euphoric, disinhibiting qualities; quiet settings accelerate the slide toward sedation and sleep. The narrow window between desired effects and unconsciousness makes environment especially important — using near water, on elevated surfaces, while driving, or alone significantly increases the consequences of losing consciousness. A sober companion who knows what was taken and when is a meaningful safety measure.
Aftercare & integration. GHB's short duration means the acute experience resolves quickly, but aftereffects can include lingering grogginess, mild confusion, and fragmented memory. Prioritize sleep, hydration, and a light meal in the hours following use.
If memory gaps occurred, piece together events with trusted companions when ready. Repeated amnesia episodes signal that dosing is too high. Users who find themselves dosing on a schedule — particularly around the clock — should recognize this as an early sign of physical dependence and consider seeking support before withdrawal becomes medically dangerous.
Recovery & Support
GHB dependence develops faster than most users expect, particularly with round-the-clock dosing. Withdrawal can be medically dangerous — do not attempt unsupervised withdrawal after sustained daily use. Medical detoxification is strongly recommended, as withdrawal can progress rapidly to delirium and seizures.
Treatment options include benzodiazepine-managed detoxification, baclofen-assisted tapering, and pharmaceutical GHB dose reduction (DeTiTap) in specialist settings. Relapse rates are high; ongoing support through addiction services, peer support groups, or specialized chemsex support programs may improve outcomes.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: The line between heavy sedation and life-threatening overdose is narrow. Red flags: unresponsive to voice or firm touch, slow or irregular breathing, blue-tinged lips or fingertips, vomiting while unconscious, or seizure-like movements.
Immediate steps:
- Call emergency services.
- Place the person in the recovery position (on their side) to prevent choking on vomit.
- Monitor breathing continuously. If breathing stops, begin rescue breathing.
- Do NOT leave the person alone. Do NOT induce vomiting. Do NOT give stimulants to try to wake them.
What to tell the dispatcher: Name the substance (GHB, G, or liquid G), estimated amount and time taken, current symptoms, and whether anything else was consumed. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for GHB. Recovery depends entirely on maintaining the airway until the drug is eliminated — typically within one to two hours.
Legal Status[edit]
GHB occupies an unusual regulatory position, simultaneously classified as a Schedule I controlled substance (illicit use) and a Schedule III prescription medication (pharmaceutical sodium oxybate) in the United States — a bifurcated arrangement unique in US drug policy. Internationally, GHB is controlled under Schedule IV of the UN Convention on Psychotropic Substances (2001). The prodrugs GBL and 1,4-BD remain unscheduled in most jurisdictions, creating a persistent regulatory gap through which pharmacologically equivalent GHB exposure remains accessible.[19]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (illicit) / Schedule III (Xyrem, Xywav) | Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000 (PL 106-172);[14] FDA-approved formulations under Schedule III with REMS[2] |
| United Kingdom | Class C (Misuse of Drugs Act 1971) | Designated June 2003[13] |
| International (UN) | Schedule IV, Convention on Psychotropic Substances | Added 2001citation needed |
| Italy | Prescription approved (Alcover) | Approved for alcohol withdrawal and dependence maintenance since 1990s[16] |
| Austria | Prescription approved (Alcover) | Approved for alcohol withdrawal and dependence maintenance since 1990s[17] |
| Canada | Schedule III (CDSA) | Controlled since 2000citation needed |
| Australia | Schedule 8 / Prohibited | Prohibited except pharmaceutical usecitation needed |
The unscheduled status of GBL and 1,4-BD under the UN Convention means these GHB prodrugs remain legally available as industrial solvents in most jurisdictions, though some countries have enacted domestic controls on their sale for human consumption.
Frequently asked questions
What is GHB?
GHB is an endogenous short-chain hydroxy acid and CNS depressant that acts primarily as a low-affinity GABA-B receptor agonist. First investigated by Henri Laborit in 1960, it is approved as sodium oxybate (Xyrem) for narcolepsy with cataplexy.
How long does GHB last?
Total duration by route of administration — Oral: 1.5 – 2.5 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for GHB?
Psychedex publishes a dosage table for GHB on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with GHB?
The highest-severity documented interactions for GHB: GHB, GBL (Lethal), Ketamine, DXM, PCP (Lethal), Opioids (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is GHB addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for GHB: tolerance builds rapid; full reset takes 10.5 days; cross-tolerance develops with baclofen, phenibut, GBL, 1,4-butanediol. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcdFuller DE, Hornfeldt CS, Kelloway JS, Stahl PJ, Anderson TF (2004) The Xyrem risk management program — Drug Safety PMID:15061684
- [2] ^abFuller DE, Hornfeldt CS (2003) From club drug to orphan drug: sodium oxybate (Xyrem) for the treatment of cataplexy — Pharmacotherapy PMID:14524654
- [3]
- [4] ^abcdPalatini P, Tedeschi L, Frison G, et al. (1993) Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers — European Journal of Clinical Pharmacology PMID:8299669
- [5]
- [6] ^abcMoitroux A, Kestens C (2023) Withdrawal syndrome following chronic use of gamma-hydroxybutyric acid (GHB) — Revue medicale de Liege PMID:37560960
references
- [1] ^abCarai MA, Lobina C, Maccioni P, et al. (2008) Gamma-aminobutyric acidB (GABAB)-receptor mediation of different in vivo effects of gamma-butyrolactone — Journal of Pharmacological Sciences PMID:18270475
- [2] ^abcdFuller DE, Hornfeldt CS, Kelloway JS, Stahl PJ, Anderson TF (2004) The Xyrem risk management program — Drug Safety PMID:15061684
- [3] ^abFuller DE, Hornfeldt CS (2003) From club drug to orphan drug: sodium oxybate (Xyrem) for the treatment of cataplexy — Pharmacotherapy PMID:14524654
- [4]
- [5] ^abcdPalatini P, Tedeschi L, Frison G, et al. (1993) Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers — European Journal of Clinical Pharmacology PMID:8299669
- [6]